Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy

Acta Neurologica Scandinavica

Volumn 127, Issue 6, 2013, Pages

  Jamroz Wisniewska, A ^a   Beltowski, J ^a   Stelmasiak, Z ^a   Bartosik Psujek, H ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Mitoxantrone; Multiple sclerosis; Paraoxonase; Paraoxonase 1 activity

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; MITOXANTRONE; PARAOXON;

ADULT; ARTICLE; CLINICAL ARTICLE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; TREATMENT DURATION;

ADULT; ANTINEOPLASTIC AGENTS; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MITOXANTRONE; MULTIPLE SCLEROSIS; OXIDATIVE STRESS;

EID: 84877925458     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12000     Document Type: Article

References (19)

1. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010;9:727-39.
2. Van Horssen J, Schreibelt G, Drexhage J et al. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med 2008;45:1729-37.
3. Besler HT, Çomoĝlu S. Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr Neurosci 2003;6:189-96.
4. Rosenblat M, Aviram M. Paraoxonases role in the prevention of cardiovascular diseases. BioFactors 2009;35:98-104.
5. Ferretti G, Bacchetti T, Principi F et al. Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Mult Scler 2005;11:677-82.
6. Jamroz-Wisniewska A, Beltowski J, Stelmasiak Z, Bartosik-Psujek H. Paraoxonase 1 activity in different types of multiple sclerosis. Mult Scler 2009;15:399-402.
7. Moghtaderi A, Hashemi M, Sharafaddinzadeh N et al. Lack of association between paraoxonase 1 Q192R polymorphism and multiple sclerosis in relapse phase: a case-control study. Clin Biochem 2011;44:795-8.
8. Marriott JJ, Miyasaki JM, Gronseth G, O'connor PW, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010;74:1463-70.
9. Horenstein MS, Van der Heide RS, L'Ecuyer TJ. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab 2000;71:436-44.
10. Mcdonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
11. Chan A, Weilbach FX, Toyka KV, Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005;139:152-8.
12. Neuhaus O, Wiendl H, Kieseier BC et al. Multiple sclerosis: mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 2005;168:128-37.
13. Kopadze T, Dehmel T, Hartung HP, Stüve O, Kieseier BC. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. Arch Neurol 2006;63:1572-8.
14. Pelfrey CM, Cotleur AC, Zamor N, Lee JC, Fox RJ. Immunological studies of mitoxantrone in primary progressive MS. J Neuroimmunol 2006;175:192-9.
15. Li JM, Yang Y, Zhu P, Zheng F, Gong FL, Mei YW. Mitoxantrone exerts both cytotoxic and immunoregulatory effects on activated microglial cells. Immunopharmacol Immunotoxicol 2012;34:36-41.
16. Bellosillo B, Colomer D, Pons G, Gil J. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B chronic lymphocytic leukaemia cells. Br J Haematol 1998;100:142-6.
17. Kolodziejczyk P, Reszka K, Lown JW. Enzymatic oxidative activation and transformation of the antitumor agent mitoxantrone. Free Radic Biol Med 1988;5:13-25.
18. Brück TB, Brück DW. Oxidative metabolism of the anti-cancer agent mitoxantrone by horseradish, lacto-and lignin peroxidase. Biochimie 2011;93:217-26.
19. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005;46:1239-47.